Market Place
Sourcing Support
Phio Announces Closing of $4 Million Concurrent Registered Direct Offering
02 Jun 2023 //
PR NEWSWIRE
Phio Announces $4 Million Concurrent Registered Direct Offering
31 May 2023 //
PR NEWSWIRE
Phio Pharma Announces Initiation of Collaborative Clinical Trial with PH-762
24 May 2023 //
PR NEWSWIRE
Phio Presents Study Showing INTASYL™ Treatment of NK Cells
18 May 2023 //
PR NEWSWIRE
Phio Pharmaceuticals receives FDA IND clearance for PH-762 trial
17 May 2023 //
CLINICAL TRIALS ARENA
Phio Pharma Announces FDA Clearance to Initiate Clinical Trial of PH-762
16 May 2023 //
PR NEWSWIRE
Phio Pharmaceuticals Reports 1Q 2023FYR &Provides Business Update
11 May 2023 //
PR NEWSWIRE
Phio Pharma Presents Preclinical Data Demons Synergy Efficacy of PD-1/CTLA-4
18 Apr 2023 //
PR NEWSWIRE
Phio Pharmaceuticals Announces $2 Million Registered Direct Offering
18 Apr 2023 //
PR NEWSWIRE
Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces
17 Apr 2023 //
PR NEWSWIRE
Phio Reports 2022 Year End Financial Results and Provides Business Update
22 Mar 2023 //
PR NEWSWIRE
Phio Appoints Robert Bitterman as President and Chief Executive Officer
22 Feb 2023 //
PR NEWSWIRE
Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
13 Feb 2023 //
PR NEWSWIRE
Phio Pharmaceuticals Announces Positive DMC Recommendation
10 Feb 2023 //
PR NEWSWIRE
Phio Pharmaceuticals Announces Reverse Stock Split
25 Jan 2023 //
PR NEWSWIRE
Phio Pharma Announces Regulatory Clearance of Trial With PH-762& AgonOx`s AGX148
06 Jan 2023 //
PR NEWSWIRE
Phio Pharmaceuticals Announces New Clinical Program to Study PH-762
21 Dec 2022 //
PRNEWSWIRE
Phio Announces New Appointments to Leadership Team, Reports on 3Q 2022 FYR
10 Nov 2022 //
PRNEWSWIRE
Phio Announces Study Results at the 37th Annual Meeting of (SITC)
10 Nov 2022 //
PRNEWSWIRE
Phio Pharmaceuticals Announces Upcoming Presentations at the SITC
06 Oct 2022 //
PRNEWSWIRE
Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762
22 Sep 2022 //
PRNEWSWIRE
Phio Announces Acceptance of 6 Abstracts at Annual Meeting of the SITC
12 Sep 2022 //
PRNEWSWIRE
Phio Pharmaceuticals Reports Q2 2022 Rusult and Provides Business Update
11 Aug 2022 //
PRNEWSWIRE
Phio Pharma Presents Study Outline of Trial with PH-762 for Advanced Melanoma
06 Jun 2022 //
PRNEWSWIRE
Phio Pharmaceuticals Presents New Data Demonstrating PH-894
16 May 2022 //
PRNEWSWIRE
Phio Pharma Reports First Quarter 2022 Financial Results
12 May 2022 //
PRNEWSWIRE
Phio Pharmaceuticals Announces Senior Leadership Personnel Change
05 May 2022 //
PRNEWSWIRE
Phio Pharma Appoints Patricia A. Bradford to its Board of Directors
02 May 2022 //
PRNEWSWIRE
Phio Pharma Initiates PIb Trial of PH-762 for Advanced Melanoma
26 Apr 2022 //
PRNEWSWIRE
Phio Pharma Selected to Present at the Tumor Immune Microenvironment Workshop
18 Apr 2022 //
PRNEWSWIRE
Phio Pharma Presents Positive New Data on PH-894 on Antitumor Efficacy
08 Apr 2022 //
PRNEWSWIRE
Phio Pharma Reports 2021 Year End Financial Results; Provides Business Update
22 Mar 2022 //
PRNEWSWIRE
Phio Pharma says Upcoming Presentation of PH-894 Data at AACR
08 Mar 2022 //
PRNEWSWIRE
Phio Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2
22 Feb 2022 //
PRNEWSWIRE
Phio Pharmaceuticals obtains clearance for melanoma treatment trial
11 Jan 2022 //
CLINICALTRIALSARENA
Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response
13 Nov 2021 //
PRNEWSWIRE
Phio Pharma Reports Q3 2021 Financial Results and Provides Business Update
10 Nov 2021 //
PRNEWSWIRE
Phio PharmaAnnounces Upcoming Presentation at the SITC 36th Annual Meeting
18 Oct 2021 //
PRNEWSWIRE
Phio Pharma Presents New BRD4 Data at AACR-NCI-EORTC International Conference
07 Oct 2021 //
PRNEWSWIRE
Phio Pharma Announces Two Upcoming Data Presentations at Scientific Conferences
30 Sep 2021 //
PRNEWSWIRE
Phio jumps 18% after mPH-3861 showed positive result
16 Sep 2021 //
SEEKINGALPHA
Phio Pharma to Participate in H.C. Wainwright 23rd Global Investment Conference
03 Sep 2021 //
PRNEWSWIRE
Phio Pharma to Participate in H.C. Wainwright 23rd Global Investment Conference
03 Sep 2021 //
PRNEWSWIRE
Phio Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021
31 Aug 2021 //
PRNEWSWIRE
Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results
12 Aug 2021 //
PRNEWSWIRE
Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat
07 Jul 2021 //
PR NEWSWIRE
Phio Pharmaceuticals Reschedules Fireside Chat
22 Jun 2021 //
PRNEWSWIRE
Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events
14 Jun 2021 //
PRNEWSWIRE
Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762
11 May 2021 //
PRNEWSWIRE
Phio Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly
11 May 2021 //
PRNEWSWIRE
Phio Announces Upcoming Data Presentations at the ASGCT and ASCO
29 Apr 2021 //
BIOSPACE
Phio Presents Positive In Vivo Data Showing Strong Tumor Control Intratumoral
09 Apr 2021 //
PRNEWSWIRE
Phio To Present New Data on PD-1 Targeting INTASYL at the 2021 AACR
11 Mar 2021 //
PRNEWSWIRE
Phio To Present New Data on PD-1 Targeting INTASYL at the 2021 AACR
11 Mar 2021 //
PRNEWSWIRE
Phio and AgonOx,Announce Collaboration on Clinical Development of Novel T Cell
01 Mar 2021 //
PRNEWSWIRE
Phio to Participate in the H.C. Wainwright BioConnect 2021 Conference
04 Jan 2021 //
PRNEWSWIRE
Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT
09 Nov 2020 //
PRNEWSWIRE
Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL
22 Jun 2020 //
PRNEWSWIRE
Phio to Host Key Opinion Leader Call on Intratumoral Therapy
08 Jun 2020 //
PRNEWSWIRE
Phio Announces +ve In Vivo Data on the Intratumoral Use of INTASYL Compounds
29 May 2020 //
PRNEWSWIRE
